IRIS
CUCINOTTA, MARIAPAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.514
NA - Nord America 1.768
AS - Asia 934
SA - Sud America 320
AF - Africa 38
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.579
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.183
US - Stati Uniti d'America 1.727
RU - Federazione Russa 1.139
SG - Singapore 337
NL - Olanda 287
CN - Cina 283
BR - Brasile 266
IE - Irlanda 257
SE - Svezia 215
DE - Germania 118
HK - Hong Kong 87
FI - Finlandia 66
GB - Regno Unito 65
FR - Francia 61
VN - Vietnam 61
IN - India 55
PL - Polonia 39
CA - Canada 21
BD - Bangladesh 15
AR - Argentina 14
TR - Turchia 14
IQ - Iraq 13
UA - Ucraina 13
CH - Svizzera 12
CZ - Repubblica Ceca 12
ES - Italia 12
CO - Colombia 11
IR - Iran 10
BE - Belgio 9
MX - Messico 9
ZA - Sudafrica 8
CI - Costa d'Avorio 7
CL - Cile 7
EC - Ecuador 7
JP - Giappone 7
PK - Pakistan 7
KE - Kenya 6
SA - Arabia Saudita 6
ID - Indonesia 5
PY - Paraguay 5
TN - Tunisia 5
AL - Albania 4
AZ - Azerbaigian 4
EG - Egitto 4
JM - Giamaica 4
KZ - Kazakistan 4
LT - Lituania 4
MA - Marocco 4
PH - Filippine 4
UY - Uruguay 4
UZ - Uzbekistan 4
AU - Australia 3
CR - Costa Rica 3
NP - Nepal 3
RO - Romania 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
BH - Bahrain 2
BY - Bielorussia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
IL - Israele 2
LB - Libano 2
LY - Libia 2
MY - Malesia 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DZ - Algeria 1
GA - Gabon 1
GR - Grecia 1
HN - Honduras 1
KG - Kirghizistan 1
KI - Kiribati 1
LK - Sri Lanka 1
LU - Lussemburgo 1
NI - Nicaragua 1
NO - Norvegia 1
PT - Portogallo 1
QA - Qatar 1
SI - Slovenia 1
SM - San Marino 1
Totale 9.579
Salva come PNG Salva come JPEG
Città #
Milan 411
Rome 355
Moscow 318
Dublin 256
Ashburn 255
Dallas 242
Chandler 215
Singapore 204
Naples 176
Nyköping 136
Beijing 123
San Jose 119
Hong Kong 86
Turin 86
Bari 75
Bologna 72
Munich 70
Palermo 65
The Dalles 63
Florence 58
Catania 51
Jacksonville 51
Dearborn 48
Genoa 48
Los Angeles 43
New York 42
Cambridge 34
Princeton 34
Warsaw 33
Lauterbourg 32
Medford 32
Des Moines 30
Messina 27
Trieste 27
Brescia 25
Modena 25
Cagliari 24
Hyderabad 24
Pisa 22
Turku 22
Ann Arbor 21
Lancaster 21
São Paulo 21
Jinan 20
Verona 20
Parma 19
Buffalo 17
Padova 17
Bergamo 16
Hanoi 16
Ho Chi Minh City 15
Pune 15
Cascina 14
Houston 14
Nanjing 14
Cosenza 13
Monza 13
Novara 12
Orem 12
Pescara 12
Prato 12
Reggio Emilia 12
San Mateo 12
Boardman 11
Bremen 11
Padua 11
Denver 10
Modugno 10
Montreal 10
Perugia 10
Udine 10
Venice 10
Atlanta 9
Brussels 9
Civitanova Marche 9
London 9
Lucca 9
Sassari 9
Shenyang 9
Taranto 9
Ancona 8
Helsinki 8
Ningbo 8
Redondo Beach 8
Rio de Janeiro 8
Wilmington 8
Abidjan 7
Brasília 7
Brooklyn 7
Eboli 7
Frankfurt am Main 7
Hebei 7
Johannesburg 7
Livorno 7
Oristano 7
Ravenna 7
Treviglio 7
Vicenza 7
Aversa 6
Brno 6
Totale 4.726
Salva come PNG Salva come JPEG
Nome #
LA LOCALIZZAZIONE ISTMICA DEL NODULO TIROIDEO MALIGNO RAPPRESENTA UN FATTORE ADDIZIONALE DI RISCHIO PER METASTASI IN PAZIENTI AFFETTI DA CARCINOMA DIFFERENZIATO DELLA TIROIDE (CDT) A BASSO RISCHIO 4.651
ACCIDENTAL DISCOVERY OF LUNG METATSTASES FROM DIFFERENTIATED THYROID CANCER BY TC-99M PERTECHNETATE SCAN IN A PATIENT WITH SECONDARY HYPERPARATHYROIDISM 208
A didactic experiment showing the Compton scattering by means of a clinical gamma camera 206
2 years-survival analysis of patients with non-small cell lung cancer by means of 2deoxy-2-[18F]fluoro-D-glucose positron emission tomography: implications of maximum standardized uptake value (SUVmax) 200
THIONAMIDES-RELATED VASCULITIS IN AUTOIMMUNE THYROID DISORDERS: REVIEW OF CURRENT LITERATURE AND CASE REPORTS 197
99mTc-Methoxy-Isobutil-Isonitrile (MIBI) scintigraphy is an useful and cost-effective tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine needle cytology (FNAC) 191
Hyperthyroidism treatment with calculated activity of 131-Radioiodine: our experience 181
Central nervous system vasculitis after starting methimazole in a woman with Graves' disease 181
Is malignant nodule topography an additional risk factor for metastatic disease in low-risk differentiated thyroid cancer? 179
Radiometabolic therapy with 131I for the ablation of the thyroid remnant in patients affected by differentiated thyroid cancer: comparison between four different activities 173
Can the position of malignant thyroid nodule be considered as additional risk factor for recurrent and/or metastatic disease in patients affected by low risk differentiated thyroid cancer? 171
A potentially misleading finding at somatostatin receptor scintigraphy: focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions 165
Oxidative Stress: Harms and Benefits for Human Health 165
Follicular variant of papillary thyroid carcinoma presenting as toxic nodule in an adolescent: coexistent polymorphism of the TSHR and Gsα genes 160
FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA PRESENTING AS A TOXIC NODULE IN AN ADOLESCENT GIRL 158
Hyperthyroidism treatment with calculated activity of 131–radioiodine 158
Can the position of malignant thyroid nodule be considered as additional risk factor for recurrent and/or metastatic disease in patients affected by low-risk differentiated thyroid cancer? 155
Is Detection of Additional Lesions in Post-Peptide ReceptorRadionuclide Therapy Scans With Respect to DiagnosticImaging Only Due to Different Affinity of Ligands?A Report of Discordance Between Diagnostic and Posttherapy Imaging Using the Same Ligand 151
Is %ΔSUVmax a Useful Indicator of Survival in Patients with Advanced Nonsmall-Cell Lung Cancer? 147
High-grade gliomas associated with abscess: description of two rare cases and role of 99mTc-Leukoscan 143
High grade gliomas associated with abscess: description of two rare cases and role of 99mTc-Leukoscan 141
Middle-Term Outcome and safety of hyperthyroid patients treated with calculated activity of radioiodine 133
IMPIEGO DEL 99mTC-MIBI PER VALUTARE IL RISCHIO DI MALIGNITA’ DEL NODULO TIROIDEO 132
Lack of association between autonomously functioning thyroid nodules and germline polymorphisms of the thyrotropin receptor and Gαs genes in a mild to moderate iodine-deficient Caucasian population 131
Our experience with peptide receptor radionuclide therapy in patients affected by pulmonary neuroendocrine tumors 130
Middle-term outcome and safety of hyperthyroid patients treated with calculated activity of radioiodine 120
Peptide receptor imaging in neuroendocrine tumors: comparison between diagnostic scintigraphy and post-therapy whole-body scan 119
Is pre-treatment SUVmax an useful indicator of survival in patients with advanced non-small-cell lung cancer? 115
Gliomas with intratumoral abscess formation: Description of new cases, review of the literature, and the role of (99m)TC-Leukoscan 108
Renal function evaluation in patients undergoing repeated peptide receptor radionuclide therapy 107
VANTAGGI DELLA DOSIMETRIA PERSONALIZZATA VS ATTIVITA’ STANDARD DI RADIOIODIO NELLA TERAPIA DELL’IPERTIROIDISMO: LA NOSTRA ESPERIENZA 101
Two-year survival prediction in patients with stage I and II non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantification 99
Stage III-IV non small cell lung cancer: the impact of SUVmax and %SUVmax in predicting survival after chemotherapy 92
RADIOIODINE UPTAKE IN ABDOMINAL DERMOID CYST IN A PATIENT WITH DIFFERENTIATED THYROID CANCER (DTC) 82
null 42
null 27
Totale 9.619
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.923
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.923
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 0 0 6
2021/2022249 1 30 1 8 15 1 29 8 1 49 30 76
2022/2023787 62 107 36 63 47 59 21 40 307 15 22 8
2023/20241.374 22 50 72 73 70 134 103 123 96 202 178 251
2024/20253.215 216 141 234 328 268 198 229 459 390 244 234 274
2025/20263.408 240 252 303 259 276 592 365 382 412 199 71 57
Totale 9.619